Incyt e Corporation   Page 1 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0 12 JUN 2018  
 
Clinical Study Protocol  
 
 
INCB [ZIP_CODE]- 207 
 
An Open- Label Phase 2 Study of INCB050465 in Participants With 
Primary Sjögren' s Syndrome  
 
Product:  INCB050465 
IND Number:  
Phase of Study:  2 
Sponsor:  Incyte Corporation 
1801 Augustine Cut- Off 
Wilmington, DE [ZIP_CODE] 
Original Protocol (Version 0):  [ADDRESS_1135029] their origin in the Declaration of 
Helsinki and conducted in a dherence to the study Protocol , applicable  Good Clinical Practices , and applicable laws 
and country- specific regulations in which the study is being conducted . 
The information in this document is confidential .  No part of this information may be duplicated, referenced, or 
transmitted in any form or by [CONTACT_61076]  (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written  consent . 
CONFIDENTIAL  

Incyt e Corporation   Page 2 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0 12 JUN 2018  
INVESTIGATOR' S AGREEMENT  
I have read the INCB [ZIP_CODE]-207 Protocol (Version 0 dated 12 JUN 2018) and agree to conduct 
the study as outlined.  I agree to maintain the  confidentiality of all information received or 
developed in connection with this Protocol. 
  
   
(Printed Name [CONTACT_7919])   
   
   
(Signature [CONTACT_7919])   (Date)  
CONFIDENTIAL  
Incyt e Corporation   Page [ADDRESS_1135030] O F ABBREVIATIONS  ..........................................................................................................8  
1. PROTOCOL SUMMARY ..........................................................................................10  
2. INTRODUCTION  ......................................................................................................14  
2.1. Background .................................................................................................................14  
2.1.1.  Sjögren's Syndrome ....................................................................................................14  
2.1.2.  Diagnosis of Sjögren's Syndrome ...............................................................................15  
2.2. Current Treatment and Unmet Needs for Sjögren's Syndrome ..................................16  
2.3. PI3Kδ in Autoimmune Diseases .................................................................................16  
2.3.1.  PI3Kδ in Sjögren's Syndrome .....................................................................................17  
2.3.2.  INCB050465 ...............................................................................................................17  
2.4. Study Rationale  ...........................................................................................................18  
2.4.1.  Scientific Rationale for Study Design  ........................................................................18  
2.4.2.  Nonclinical Toxicology and Safety Margins  ..............................................................18  
2.4.3.  Justification for Dose ..................................................................................................19  
  
2.5.1.  Potential Risks of INCB050465 Based on Preclinical Safety ....................................19  
2.5.2.  Potential Risks of INCB050465 Based on Clinical Safety .........................................21  
2.5.3.  Potential Benefits of INCB050465 in Sjögren's Syndrome ........................................22  
2.5.4.  Overall Risk/Benefit Statement ..................................................................................22  
3. OBJECTIVES AND ENDPO INTS  ............................................................................23  
4. STUDY DESIGN  .......................................................................................................24  
4.1. Overall Design  ............................................................................................................24  
4.2. Overall Study Duration  ...............................................................................................25  
4.3. Study Termination  ......................................................................................................25  
5. STUDY POPULATION  .............................................................................................26  
5.1. Inclusion Criteria  ........................................................................................................26  
5.2. Exclusion Criteria  .......................................................................................................27  
5.3. Lifestyle Considerations .............................................................................................29  
5.3.1.  Meals and Dietary Restrictions  ...................................................................................29  
5.4. Screen Failures  ............................................................................................................29  
5.5. Replacement of Participants  .......................................................................................29  
CONFIDENTIAL  

Incyt e Corporation   Page 4 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0 12 JUN 2018  
6. STUDY TREATMENT  ..............................................................................................30  
6.1. Study Treatment Administered  ...................................................................................30  
6.2. Preparation, Handling, and Accountability ................................................................30  
6.3. Measures to Minimize Bias:  Randomization and Blinding  .......................................31  
6.4. Study Treatment Compliance  .....................................................................................31  
6.5. Dose Modifications .....................................................................................................31  
6.5.1.  Management of  Urgent Toxicities  .............................................................................31  
6.5.2.  Criteria and Procedures for Dose Interruptions and Adjustments of Study 
Drug  ............................................................................................................................31  
6.5.3.  Criteria for Permanent Discontinuation of INCB050465 ...........................................32  
6.6. Concomitant Medications and Procedures .................................................................32  
6.6.1.  Permitted Medications and Procedures ......................................................................33  
[IP_ADDRESS].  Prophylaxis for Pneumocystis jirovecii  Pneumonia ...................................................33  
[IP_ADDRESS].  Nonprescription Therapi[INVESTIGATOR_819467]ögren's Syndrome ...................................................33  
6.6.2.  Restricted Medications and Procedures  ......................................................................33  
6.6.3.  Prohibited Medications and Procedures .....................................................................34  
6.7. Treatment After the End of the Study .........................................................................34  
7. DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT DISCONTINUATION/WITHDRAWAL  ..................................................................[ADDRESS_1135031] to Follow- Up.......................................................................................................36  
8. STUDY ASSESSMENTS AND PROCEDURES  ......................................................37  
8.1. Administrative and General Procedures .....................................................................37  
8.1.1.  Informed Consent Process ..........................................................................................37  
8.1.2.  Screening Procedures  ..................................................................................................38  
8.1.3.  Interactive Response Technology Procedure ..............................................................38  
8.1.4.  Distribution of Reminder Cards and/or Diaries ..........................................................38  
8.1.5.  Demography and Medical History ..............................................................................39  
[IP_ADDRESS].  Demographics and General Medical History  .............................................................39  
[IP_ADDRESS].  Disease Characteristics and Treatment History  ..........................................................39  
CONFIDENTIAL  
Incyt e Corporation   Page 5 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0 12 JUN 2018  
8.2. Efficacy Assessments  .................................................................................................39  
8.2.1.  Ultrasound of Salivary Glands ....................................................................................39  
8.2.2.  EULAR Sjögren's Syndrome Disease Activity Index  ................................................39  
8.2.3.  Salivary Flow  ..............................................................................................................39  
8.2.4.  Patient -Reported Outcomes  ........................................................................................40  
[IP_ADDRESS].  Dryness Questionnaire ................................................................................................40  
[IP_ADDRESS].  EULAR Sjögren's Syndrome Patient Reported Index ................................................40  
[IP_ADDRESS].  Patient Global Impression of Change Questionnaire ..................................................40  
[IP_ADDRESS].  Female Sexual Function Index  ...................................................................................40  
[IP_ADDRESS].  PROMIS Fatigue Short Form .....................................................................................40  
[IP_ADDRESS].  European Quality Of Life 5 Dimensions Questionnaire .............................................40  
8.2.5.  Health Economics  .......................................................................................................40  
8.3. Safety Assessments  .....................................................................................................40  
8.3.1.  Adverse Events  ...........................................................................................................41  
8.3.2.  Physical Examinations  ................................................................................................41  
8.3.3.  Vital Signs  ..................................................................................................................41  
8.3.4.  Electrocardiograms  .....................................................................................................42  
8.3.5.  Laboratory Assessments  .............................................................................................42  
[IP_ADDRESS].  Pregnancy Testing  ......................................................................................................43  
[IP_ADDRESS].  Serology and Virology ................................................................................................44  
[IP_ADDRESS].  Tuberculosis Testing ...................................................................................................44  
  
  
  
  
  
8.6. End of Treatment ........................................................................................................46  
8.7. Safety Follow -Up ........................................................................................................46  
9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING,  FOLLOW -UP, AND REPORTING  ......................46  
9.1. Definition of Adverse Event .......................................................................................46  
9.2. Definition of Serious Adverse Event ..........................................................................47  
9.3. Recording and Follow-Up of Adverse Events and/or Serious Adverse Events .........[ADDRESS_1135032] OF TABLES  
Table 1:  Primary and Key Secondary Objectives and Endpoints .............................................10  
Table 2:  Key Study Design Elements  .......................................................................................10  
Table 3:  Schedule of Activities  .................................................................................................12  
Table 4:  Schedule of Laboratory Assessments  .........................................................................13  
Table 5:  Objectives and Endpoints ...........................................................................................23  
Table 6:  Exclusionary Laboratory Values  ................................................................................29  
Table 7:  Study Treatment Information  .....................................................................................30  
Table 8:  Criteria for Interrupting, Re starting, or Discontinuing Study Drug ...........................32  
Table 9:  Electrocardiogram Schedule .......................................................................................42  
Table 10:  Required Laboratory Analytes  ....................................................................................[ADDRESS_1135033] OF ABBREVIATION S 
Abbreviations and 
Special Terms  Definition  
AE adverse event  
AECG  American −European Consensus Group 
ALT  alanine aminotransferase  
ANC  absolute neutrophil count 
  
  
AST  aspartate aminotransferase  
AUC  area under the plasma or serum concentration curve  
BTK  Bruton's tyrosine kinase  
CAML  calcium -modulating ligand 
CD cluster of differentiation  
Cmin minimum observed plasma or serum concentration 
CTCAE  Common Terminology Criteria for Adverse Events 
CXCL13  CXC motif chemokine ligand 1 3 
CYP  cytochrome P450  
DLT  dose- limiting toxicity  
ECG  electrocardiogram  
eCRF  electronic case report form  
eGFR  estimated glomerular filtration rate  
EOT  end of treatment  
EQ-5D European Quality Of Life 5 Dimensions questionnaire 
ESSDAI  EULAR Sjögren's Syndrome Disease Activity Index  
ESSPRI  EULAR Sjögren's Syndrome Patient Reported Index 
EULAR  European League Against Rheumatism 
FAS full analysis set  
FSFI  Female Sexual Function Index 
FSH follicle -stimulating hormone 
GLP  Good Laboratory Practice  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus 
IB Investigator's Brochure  
IC50 concentration that results in 50% inhibition  
CONFIDENTIAL  

Incyt e Corporation   Page 9 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0 12 JUN 2018  
Abbreviations and 
Special Terms  Definition  
IC90 concentration that results in 90% inhibition  
ICF informed consent form  
ICH International Conference on Harmonisation  
IEC independent ethics committee  
  
IL interleukin  
IRB institutional review board  
IRT interactive response technology 
IV intravenous 
JAK Janus kinase  
MedDRA  Medical Dictionary for Regulatory Activities  
PBMC peripheral blood mononuclear cells 
PD pharmacodynamic  
PGIC  Patient Global Impression of Change questionnaire 
PI3Kδ  phosphatidylinositide 3- kinase delta isoform  
PJP Pneumocystis jirovecii  pneumonia 
  
PROMIS  Patient-Reported- Outcomes Measurement Information System  
QD once daily  
QTcF  QT interval corrected for heart rate using Fridericia's formula  
RA rheumatoid arthritis  
RNA  ribonucleic acid  
SGUS  salivary gland ultrasound 
SLE systemic lupus erythematosus 
SoA schedule of activities  
SS Sjögren's syndrome  
T3, T4  triiodothyronine and thyroxine (thyroid hormones)  
TB tuberculosis  
TEAE  treatment -emergent adverse event, AEs reported for the first time or worsening of 
a pre- existing event after first dose of stu dy treatment  
TNF  tissue necrosis factor  
Treg  regulatory T cell  
ULN upper limit of normal 
 
CONFIDENTIAL  

Incyte Corporation   Page 12 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0 12 JUN 2018  
Table 3: Schedule of A ctivitie s 
 Screening  
(Day -28 
to Day -1) Day 1  Week 2  
(± 3 Days ) Week 4  
(± 7 Days ) Week 8  
(± 7 Days ) Week 12/  
EOT  
(± 7 Days ) Safety Follow -Up 
(30 Days [+7 Days ] 
After Last Dose of 
Study Drug ) Comments  
Administrative Procedures  
Informed consent  X        
Contact I RT X X X X X X   
Inclusion/exclusion criteria  X X       
Medical and medication history  X        
Concomitant medications  X X X X X X X  
Dispense reminder card   X X X X    
Administer study drug during visit   X X X X    
Dispense study drug   X X X X    
Drug accountability and compliance 
assessment    X X X X   
Administer PJP prophylaxis if 
needed *  X X X X X X From Day [ADDRESS_1135034] dose of study drug . 
*See Section  [IP_ADDRESS] . 
Safety Assessments  
AE assessment  X X X X X X X  
Comprehensive physical examination  X      X  
Targeted physical examination   X X X X X  Body systems with symptoms should 
be physically examined . 
Vital signs  X X X X X X X Measure height  at screening only . 
12-lead ECG  X X X   X X* *Standard ECG . 
Efficacy Assessments  
Ultrasound of parotid and 
submandibular salivary glands   X*  X  X  *Schedule ultrasound 2 weeks before 
Day 1 to ensure results availability.  
Measurement of total unstimula ted 
salivary flow  X X  X X X   
Measurement of total stimulated 
salivary flow  X* X  X X X  *Documented measurement within 
12 weeks before screening visit.  
Questionnaire for dryness of eyes, 
mouth , and (females only) vagina  X X  X X X   
ESSDAI assessment  X X  X X X   
ESSPRI questionnaire  X X  X X X   
PGIC  questionnaire  X X  X X X   
FSFI questionnaire  X X  X X X  Female participants only . 
PROMIS Fatigue questionnaire  X X  X X X   
EQ-5D questionnaire  X X  X X X   
CONFIDENTIAL  
Incyte Corporation   Page 13 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0 12 JUN 2018  
Table 4: Schedule of Laboratory Assessments  
 Screening  
(Day -28 to 
Day -1) Day 1 Week 2  
(± 3 days ) Week 4  
(± 7 Days ) Week 8  
(± 7 Days ) Week 12/EOT  
(± 7 Days ) Safety Follow -Up 
(30 Days [ + 7 Days] 
After Last Dose of 
Study Drug ) Comments  
Clinical Laboratory  Assessments  
Serum chemistries  X X X X X X X  
Hematology  X X X X X X X  
Serum pregnancy  test X      X All female participants of 
childbearing potential.  
FSH X       To document hormonal 
menopause  defined as 
amenorrhea of at least 
[ADDRESS_1135035]   X X X X X  Female participants of 
childbearing potential  only. 
Thyroid function  X        
Serology – HIV,  HBV , and HCV, 
viral load  reflex if required  X        
TB test  X       QuantiFERON -TB Gold test or 
T-spot.TB . 
Urinalysis  X     X X  
 
CONFIDENTIAL  

Incyte Corporation   Page 23 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
3. OBJECTIVES AND ENDPO INTS  
Table 5 presents the objectives and endpoints. 
Table 5: Objectives and Endpoints  
Objectives Endpoints  
Primary  
To determine the impact of INCB050465 on 
salivary gland echostructure.  • Proportion of participants with a [ADDRESS_1135036] of INCB050465 on 
salivary CXCL13  • Change and percent change from baseline in salivary CXCL13 levels at Week  4 and Week  12. 
To assess the efficacy of INCB050465  • Change and percent change in stimulated and unstimulated whole salivary flow fr om baseline at 
Weeks 4, 8, and 12. 
• Change and percent change in ESSDAI at Week  12. 
• Change and percent change in ESSPRI at Week s 4, 
8, and 12. 
• Change and percent change in symptom scores for dryness of eyes, mouth , and vagina at Week s 4, 8, 
and 12. 
• Proportions of participants in each PGIC  category 
at Week s 4, 8, and 12. 
• Change and percent change in PROMIS Fatigue short form  at Week s 4, 8, and 12. 
• Change and percent change in FSFI  at Week s 4, 8, 
and 12 (female participants only).  
• Change and percent change in EQ -5D at Week s 4, 
8, and 12. 
To evaluate the safety and tolerability of INCB050465 • Frequency, duration, and severity of AEs, clinical laboratory test results, vital sign results, ECGs, and physical exam ination  findings.  
CONFIDENTIAL  

Incyte Corporation   Page 24 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
Table 5: Objectives and Endpoints  (Continued)  
4. STUDY DESIGN 
4.1. Overall Design  
This is a sin gle group , open -label study of the impact of PI3Kδ inhibitor INCB050465 on signs 
and symptoms of SS.  Twelve participants meeting the inclusion criteria and none of the 
exclusion criteria will be enrolled.  Participants will receive treatment with INCB0504 [ADDRESS_1135037] regularly scheduled study visits at screening, Day 1 ( baseline; first day of 
dose administration), and at the end of Weeks 4, [ADDRESS_1135038] safety laboratory assessments . Participants will complete 
questionnaires regarding signs and symptoms of disease at each study visit. 
Ultrasound measurement of the parotid and submandibular glands will be performed on Day  1 
(before the first dose) and after 4 and 12 weeks of treatment.  Ultrasound of glands will be 
performed in the longitudinal and transverse planes with  participants  in a supi[INVESTIGATOR_2547].  The  
ultrasound images will be  evaluated for quality then  transmitted to a central vendor for reading 
and data summarization.   
The echostructure of each gland on B- mode images will be grad ed on a 5-point scale (0 to 4):   
• Grade 0 :  normal homogeneous gland. 
• Grade 1 :  small hypoecho ic areas with hyperechoic bands. 
• Grade 2 :  multiple hypoecho ic areas less than 2 mm . 
• Grade 3 :  multiple hypoechoic areas 2 to 6 mm.  
• Grade 4 :  multiple hypoechoic areas larger than 6 mm.   
For each timepoint, 4 grades will be obtained, one for each parotid and submandibular gland.  
The SGUS score is the numeric sum of the 4 individual grades (maximum score of 16).  
Instructions for conducting and transmitting ultrasound measurements will be provided in the Study M anual.  
CONFIDENTIAL  

Incyte Corporation   Page 25 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
Stimulated and unstimulated salivary flow will be performed at baseline and after 4, 8 , and 
12 weeks of treatment.  Instructions for performing salivary flow measurements will be  provided 
in the Study M anual.  
PJP prophylaxis:   Prior treatment with prednisone or equivalent may represent a risk factor for 
PJP in combination with other immunosuppressants.  Participants who have received prednisone 
≥ 20 mg per day (or equivalent) within 60 days before  baseline are excluded.  Participants 
receiving ≥  10 mg to < 20  mg of prednisone (or equivalent) may be a t increased risk for PJP , and 
prophylaxis should be considered for these participants, particularly if they have a history of PJP 
or have recently received any immunosuppressive therapy that may represent and increased risk.  
Participants receiving <  [ADDRESS_1135039] PJP prophylaxis therapi[INVESTIGATOR_819468]-sulfamethoxazole, 
atovaquone, dapsone with or without pyrimethamine, and pentamidine ( Baden et al 2012).  Due 
to reports of cross-sensitivity between sulfonamides and dapsone, all participants who have a 
known or suspected allergy to sulfonamides must receive either inhaled pentamidine or atovaquone for PJP prophylaxis.  Prophylaxis should be given while participants are receiving 
study drug and should continue for at least [ADDRESS_1135040] safety laboratory assessments . 
Week 12 will correspond to the EOT.  A safety follow up visit will occur 30 (+7) days after the last dose of study drug. 
4.2. Overall Study Duration  
Individual participant s will participate for a duration of up to 21 weeks (4 weeks screening, 
12 weeks treatment, 4 -5 weeks safety follow-up; s ee Figure  1). 
The study begins when the first participant signs the ICF.  The end of the study is defined as the 
date of the last visit of the last participant in the study . 
A participant is considered to have completed the study if he/she has completed all study visits , 
including the follow- up visit.  
The investigator will be expected to monitor for and report any SAEs, AEs of special interest, 
and pregnancies as detailed in Section  9.  The remain ing participants are considered to be on 
study until a discontinuation criterion is met and written notification is provided to the sponsor. 
4.3. Study Termination  
The investigator retains the right to terminate study participation at any time, according to the  
terms specified in the study contract .  The investigator is to notify the IRB /IEC in writing of the 
study's completion or early termination, send a copy of the notification to the sponsor or 
sponsor' s designee, and retain 1  copy for the site study regulat ory file.  
The sponsor may terminate the study electively, or if required by [CONTACT_352931] .  If the study 
is terminated prematurely, the sponsor or designee will notify the investigators, the IRBs and 
IECs, and regulatory bodies of the decision and reason for termination of the study. 
CONFIDENTIAL  

Incyte Corporation   Page 27 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Diagnosis of secondary SS according to the revised AECG criteria (eg, the presence of a 
previously diagnosed or a present diagnosis of RA , SLE , systemic sclerosis, mixed 
connective tissue disease, polymyositis, dermatomyositis, immunoglobulin G4 -related 
disorder, sarcoido sis, or any other defined autoimmune rheumatologic disorder). 
a. NOTE:  Nonrheumatologic autoimmune disorders ( eg, Hashimoto thyroiditis, 
alopecia, vitiligo, Type 1 diabetes mellitus ) do not constitute an exclusion; the 
medical monitor should be consulted if there are questions regarding a specific 
participant 's disease history or diagnosis.  
2. Concurrent conditions and history of other diseases: 
a. History or clinical manifestations of significant unstable metabolic, hepatic, renal, 
hematologic, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders. 
b. Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, and or cardiac conduction issues within 180 days of the date of study drug administration.  
c. Current [LOCATION_001] Heart Association Class II to IV congestive heart failure or uncontrolled arrhythmia. 
d. History of osteomyelitis, PJP , or bronchiectasis. 
e. Active bacterial, fungal, parasitic, or viral infection that requires antibiotic thera py.  
Participants  with acute infections requiring treatment should delay 
screening/enrollment until the course of therapy has been completed and the event is considered resolved.  Prophylactic antibiotics will be permitted if they have been started at leas t 28 days before  the screening visit.  
f. History within 6 mo nths before  screening, or current presence at screening, of poorly 
healing wound and/or cutaneous ulcers. 
g. Prior head or neck irradiation. 
h. History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opi[INVESTIGATOR_1649], would interfere with full participation in the study, 
including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.  
3. Positive test results for TB from the QuantiFERON -TB Gold test or T-spot.TB test at 
screening .  If a result is indeterminate, the test should be repeated.  If the repeat test result 
is positive, the participant  is excluded.  I f the repeat test result is indeterminate, a purified 
protein derivative skin test should be done, and if there is < [ADDRESS_1135041] results for HIV  antibody, hepatitis B surface antigen , hepatitis B 
surface antigen antibody, HBV core antibody, or HCV (HCV antibody with positive 
HCV- RNA) at screening . 
5. Severely impaired live r function (Child-Pugh Class C). 
CONFIDENTIAL  
Incyte Corporation   Page 28 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
6. Prior or ongoing therapy with: 
a. Any drug that inhibits PI3K (examples of drugs targeting this p athway include but 
are not limited to leniolisib, seletalisib, INCB040093, idelalisib, and duvelisib) at 
any time before baseline or during study. 
b. Immunologic or other immunosuppressive therapy, or B- cell targeted therapy (eg, 
rituximab, other anti-CD20 agents, anti-CD19 agents, anti-CD22 agents, anti-CD52 agents) or LyS-targeted therapy (eg, belimumab, CAML interactor) or 
other biologic investigational agent (eg, CD40L antibody) or cyclophosphamide within the prior 365 days before baseline or during study. 
c. BTK inhibitors (examples of drugs targeting this pathway include but are not 
limited to ibrutinib and PCI32765) within 90 days before baseline or during study. 
d. Use of anti -TNFα  therapy, IL -1−receptor antagonist, monoclonal antibody to 
IL-1, costimulation modulator, monoclonal antibody to IL- 6 or IL -6−receptor, 
monoclonal antibody to IL-17, monoclonal antibody to IL-23, JAK inhibitor, 
IV immunoglobulin, plasmapher esis, or Staph protein A column within [ADDRESS_1135042] 60 days as a stable regimen and agrees to continue taking the same preparation at the same dose regimen during the course of the study.  
g. Antimala rials, if ongoing, should be stable within 60 days of baseline and be 
anticipated to remain stable throughout the 12-week study assessment period. 
h. Glucocorticoids at doses ≥ [ADDRESS_1135043] be stable within 30 days of baseline and be anticipated to 
remain stable throughout the 12- week study assessment period.  
i. Use of ant icholinergics within 30 days before baseline or during study. 
j. Use of any potent cytochrome CYP3A4 inhibitors or inducers within 14 days or 
5 half -lives (whichever is longer) before baseline or anticipated during the study. 
k. Use of cholinergic agents such as pi[INVESTIGATOR_819469] 12 hours of salivary flow visits at Day 1  and Weeks 4, 8, and 12. 
7. Receipt of any live vaccine in the 30 days before  screening.  NOTE:   Participants will not 
be allowed to receive live or attenuated vaccines during their participation in the study or 
until [ADDRESS_1135044] dose of study medication with the exception of influenza vaccine.  
8. No major surgery within 30 days before screening.  Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.  
CONFIDENTIAL  
Incyte Corporation   Page 29 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
9. Current alcohol or drug use that, in the opi[INVESTIGATOR_871], will interfere with the 
participant's ability to comply with the dose  regimen and study evaluations. 
10. Laboratory values at screening defined in Table 6. 
Table 6: Exclusionary Laboratory Values 
Laboratory Parameter  Exclusion Criterion  
Hematology  
Platelets  ≤ 100 × 109/L 
ANC  ≤ 1.5 × 109/L 
Hepatic  
ALT  >[ADDRESS_1135045]  >[ADDRESS_1135046] 
Renal  
eGFR  Participants with inadequate renal function defined as eGFR 
≤ 50 mL/min  
11. Women who are pregnant  or breastfeeding.  
12. Any condition that would, in the investigator's judgment, i nterfere with full participation 
in the study, including administration of study drug /treatment and attending required 
study visits; pose a significant risk to the participant; or interfere with interpretation of 
study data.  
13. Inability of the participant (o r parent, guardian, or legally authorized representative) to 
comprehend the ICF or unwilling ness to sign the ICF. 
5.3. Lifestyle Considerations  
No restrictions are required.  
5.3.1. Meals and Dietary Restrictions  
Not applicable.  
5.4. Screen Failures  
Screen failures are defi ned as participants who consent to participate in the clinical study but are 
not subsequently entered in the study. 
Tests with results that fail eligibility requirements may be repeated once during screening if the 
investigator believes the result to be not consistent with the participant's clinical status .  
Additionally, a participant who fails screening may repeat the screening process [ADDRESS_1135047] study drug administration daily in a diary. 
Table 7: Study Treatment Information  
Study treatment name:  [CONTACT_147081]050465 
Dose formulation:  Tablet  
Unit dose str ength/ dose level:   
Route of administration:  Oral 
Administration instructions:  INCB050465 will be taken QD, orally with water  and without regard 
to food. 
Packaging and labeling: INCB050465 will be packaged in high -density polyethylene bottles.  
Storage: Ambient (15°C -30°C/59°F-86°F)  
6.2. Preparation , Handling , and Accountability  
Only participants enrolled in the study may receive study treatment , and only authorized site 
staff may supply or administer study treatmen t.  All study treatment  must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.  
The investigator (or designee)  is responsible for study t reatment  accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records).  Inventory and 
accountability records must be maintained and readily available for inspection by [CONTACT_147117] .  The 
investigator or designee must maintain records that document: 
• Delivery of study drug to the study site.  
• Inventory of study drug at the site. 
• Participant use of the study drug, including pi[INVESTIGATOR_819470]. 
• Return of study drug to the investigator or designee by [CONTACT_4317]. 
The investigational product must be used only in accordance with the Protocol.  The investigator 
will also maintain records adequately documenting that the participants were provided the 
specified study drug.  These records should include dates, quantities, and any available batch or serial numbers or unique code numbers assigned to the investigational product and study 
participants.  
Completed accou ntability records will be archived by [CONTACT_779] .  The investigator or designee will 
be expected to collect and retain all used, unused, and partially used containers of study drug until verified by [CONTACT_11200] (unless otherwise agreed to by [CONTACT_456]).  At the 
CONFIDENTIAL  

Incyte Corporation   Page [ADDRESS_1135048] 
operating procedures.  If local procedures mandate o n-site destruction of investigational supply, 
the site should (where local procedures allow) maintain the investigational supply until the study 
monitor inspects the accountability records in order to evaluate compliance and accuracy of 
accountability by t he investigative site .  At sites where the study drug is destroyed before 
monitor inspection, the monitors rely on documentation of destruction per the site SOP. 
Further guidance and information for the final disposition of unused study treatments are 
provided in the study materials provided to sites.  
6.3. Measures to Minimize Bias:  Randomization and Blinding  
Not applicable.  
6.4. Study Treatment Compliance  
Compliance with study drug should be emphasized to the participant by [CONTACT_14523], and 
appropriate steps should be taken to optimize compliance during the study .  Compliance with  
INCB050465 will be calculated by [CONTACT_819476]/designee (tablet counts).  Participants will be 
instructed to bring all study drug with them to the study visits in order for site personnel to 
conduct tablet counts to assess study drug accountability.  The drug accountability 
documentation will be used by [CONTACT_819477]. 
6.5. Dose Modificat ions 
6.5.1. Management of  Urgent Toxicities  
Investigators may employ any measures or concomitant medications necessary to optimally treat 
the participant after discussion with the sponsor (whenever possible). 
6.5.2. Criteria and Procedures for Dose I nterruptions and Adjustments of Study Drug  
Safety concerns should be discussed with the sponsor immediately upon occurrence or awareness 
to determine if the participant should continue or discontinue study treatment. 
There are no dose modifications in this study.  In some circumstances, it may be necessary to 
temporarily interrupt treatment with INCB050465 as a result of AEs or laboratory abnormalities that have an unclear relationship to the study drug (see  Table 8) .  Except in cases of emergency, 
it is recommended that any laboratory findings be confirmed and that the investigator consult with the sponsor 's medical monitor (or other representative of the sponsor) before temporarily 
interrupting study drug.  Particip ants who experience a recurrence of the AEs or laboratory 
abnormalities upon restarting the study drug may have the study drug permanently discontinued. 
Instructions for dose interruptions for INCB050465 are outlined in Table 8.  Individual decisions 
regarding dose interruptions should be made using clinical judgment in consultation with the 
medical monitor (whenever possible), taking into account relatedness of the AE to the study 
treatment and the participant's und erlying condition.  Adverse events that have a clear alternative 
explanation, or transient (≤ 72 hours) abnormal laboratory values without associated clinically 
CONFIDENTIAL  
Incyte Corporation   Page 32 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
significant signs or symptoms, may be exempt from dose  interruption.  Dose interruptions may 
occur at any time during the 12 weeks of administration. 
Table 8: Criteria for Interrupting, Restarting, or Discontinuing Study Drug  
ADVERSE EVENT  ACTION TAKEN  
Chemistry  
• AST and/or ALT is > 3.0 × ULN.  Step 1:   Interru pt study drug up to 2 weeks (14 days) until the 
toxicity has resolved to ≤ Grade 1 except by [CONTACT_741045].  
Step 2:   Restart study drug and monitor as clinically indicated.   
• AST and/or ALT is >  5.0 × ULN  Discontinue study drug administration and follow -up per Protocol.   
Hematology  
• ANC ≤ 1.0  × 109/L, unles s due to 
underlying disease.  
• Platelet count is 50  × 109/L to <  75 × 109/L, 
unless due to underlying disease.  Step 1:   Interrupt study drug up to 2 weeks (14 days) until the 
toxicity has resolved to ≤ Grade 1 or pretherapy baseline.  
Step 2:   Restart study d rug and monitor as clinically indicated.  
• Grade 4 ANC (< 0.5  × 109/L). 
• ≥ Grade  [ADDRESS_1135049] 38.5°C OR with ≥  Grade 3 infection.  
• Platelet count is < 50  × 109/L. Discontinue study drug administration and follow -up per Protocol.   
Other toxicities  
• Any Grade 1 or Grade 2 toxicity.  Continue study drug administration and treat the toxicity; monitor 
as clinically indicated.  
• Any Grade 3 toxicity, if clinically 
significant and not manageable by 
[CONTACT_90994].  Step 1:   Interrupt stu dy drug up to 2 weeks (14 days), until 
toxicity resolves to ≤ Grade 1.  
Step 2:   Restart study drug and monitor as clinically indicated.   
• Any recurrent Grade 3 toxicity after dose restart . Discontinue study drug administration and follow -up per Protocol.   
• Any other Grade 4 toxicity.  Discontinue study drug administration and follow -up per Protocol.  
6.5.3. Criteria for Permanent Discontinuation of INCB050465 
The occurrence of unacceptable toxicity not caused by [CONTACT_819478].  Unacceptable toxicity is defined as follows: 
• Occurrence of an AE that is related to treatment with the study drug that, in the judgment of the investigator or the sponsor' s medical monitor, compromise s the participant's ability 
to continue study-specific procedures or is considered to not be in the participant ’s best 
interest.  
• Persistent AE requiring a delay of therapy for more than 2 weeks without resolution of 
the AE.  A greater treatment delay requires approval by [CONTACT_456] 's medical monitor.  
6.6. Concomitant Medications  and Procedures  
All concomitant medications and treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF.  Any 
prior medication received up to [ADDRESS_1135050] dose of study treatment should be recorded for SAEs as defined in Section 9.3.  Concomitant treatments/procedures that are 
required to manage a participant's medical condi tion during the study will also be recorded in the 
eCRF.  The medical monitor should be contact[CONTACT_31182]. 
6.6.1. Permitted Medications and Procedures  
[IP_ADDRESS]. Prophylaxis for Pneumocystis jirovecii  Pneumonia  
Prior treatment with prednisone or equivalent may represent a risk factor for PJP in combination 
with other immunosuppressants.  Participants who have received prednisone ≥ 20 mg per day (or equivalent) within 60 days before  baseline are excluded.  Participants  receiving ≥ 10 to < 20 mg 
of prednisone (or equivalent) may be at increased risk for PJP, and prophylaxis should be considered for these participants , particularly if they have a history of PJP or have recently 
received any immunosuppressive therapy that may represent an increased risk.  Participants 
receiving < [ADDRESS_1135051] some potential risk; however, PJP prophylaxis is not generally required for these participants and should be considered only in exceptional circumstances and in consultation with the medical monitor as needed. 
Examples of standard PJP prophylaxis therapi[INVESTIGATOR_819468]-sulfamethoxazole, atovaquone, dapsone with or without pyrimethamine, and pentamidine ( Baden et al 2012).   Due 
to reports of cross-sensitivity between sulfonamides and dapsone, all participants who have a 
known or suspected allergy to sulfonamides must receive either inhaled pentamidine or 
atovaquone for PJP prophylaxis.  Prophylaxis should be given while participa nts are receiving 
study drug and should continue for at least [ADDRESS_1135052] dose of study drug. 
[IP_ADDRESS]. Nonprescription Therapi[INVESTIGATOR_819467]ögren's Syn drome  
Use of nutraceuticals, ayurvedic, herbal, and other nonprescription therapi[INVESTIGATOR_819471] d with  investigator review  provided the participant  has been taking the therapy for at 
least 60  days as a stable regimen and agrees to continue taking the same preparation at the same 
dose during the course of the study. 
6.6.2. Restricted Medications  and Procedur es 
• Inducers of CYP3A4 ( see Study Manual ) are discouraged, and investigators should seek 
other options if available. 
• Moderate CYP3A4 inhibitors ( see Study Manual ) are discouraged, and investigators 
should seek other options if available. 
• Administration of g lucocorticoids at doses of [ADDRESS_1135053] be stable within 30 days 
of Day 1 and be anticipated to remain stable throughout the 12- week study assessment 
period. 
CONFIDENTIAL  
Incyte Corporation   Page 34 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
• Antimalarials, if ongoing , should be stable within 60 days of Day 1 and be anticipated to 
remain stable throughout the 12- week study assessment period.  
6.6.3. Prohibited Medications  and Procedures  
The following medications and procedures are prohibited during the study from s creening 
through the f ollow-up visit and before  the study as indicated for indi vidual medications : 
At any  time before baseline (Day 1):  
• Any drug that inhibits PI3K (examples of drugs targeting this pathway include but are not 
limited to leniolisib, seletalisib, INCB040093, idelalisib, and duvelisib). 
Within 1 year (365 days) before  baseline (Day 1):  
• Immunologic or other immunosuppressive therapy, or B- cell targeted therapy (eg 
rituximab, other anti -CD-19 agents, anti -CD-20 agents, anti- CD-22 agents, anti CD52 
agents) or LyS-targeted therapy (eg, belimumab, CAML interactor) or other biologic 
investigational agent (eg, CD -40L antibody) or cyclophosphamide. 
• Anti- TNFα therapy, IL -1−receptor antagonist, monoclonal antibody to IL-1, 
costimulation modulator, monoclonal antibody to IL- 6 or IL -6−receptor, monoclonal 
antibody to IL-17, monoclonal antibody to IL-23, JAK inhibitor, IV immunoglobulin, 
plasmapheresis, or Staph protein A column. 
Within 3 months (90 days) before baseline (Day 1):  
• Any experimental drug therapy for SS.  
• BTK inhibitors (examples of drugs targeting this pathway include but are not limited to ibrutinib and PCI32765). 
Within 2 months (60 days) before baseline (Day 1):  
• Glucocorticoids at doses > 20 mg prednisone equivalents. 
Within 1  month (30 days) before baseline (Day 1):  
• Anticholinergics. 
• Receipt of any live vaccine.  Note p articipants  will not be allowed to receive live or 
attenuated vaccines during their participation in the study or until [ADDRESS_1135054] 
dose of study medication with the exception of influenza vaccine. 
Within 2 weeks (14 days) before baseline (Day 1 ): 
• Any potent CYP 3A4 inhibitors or inducers within 14 days or 5 half- lives (whichever is 
longer) before the first dose of INCB050465 or anticipated during the study. 
Within 12 hours (< 1 day) before baseline (Day 1):  
• Cholinergic agents such as pi[INVESTIGATOR_1227]. 
6.7. Treatment After the End of the Study  
There is no treatment after the end of the study.  
CONFIDENTIAL  
Incyte Corporation   Page 35 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
7. DISCONTINUATION OF S TUDY TREATMENT AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
7.1.1. Reasons for Discontinuation 
Participants must  be discontinued from study treatment for the following reasons: 
• The participant becomes pregnant. 
• Consent is withdrawn.   
Note:  Consent withdrawn means that the participant has explicitly indicated that they 
do not want to be followed any longer; in this case no f urther data, except data in 
public domain, may be solicited from or collected on the participant.  
• Further participation would be injurious to the participant's health or well- being , in 
the investigator 's medical judgment.  
• Unacceptable toxicity as noted in  Section  6.5.3. 
• The study is terminated by [CONTACT_456]. 
• The study is terminated by [CONTACT_19407], IRB, or IEC. 
A participant  may be discontinued from study treatment as follows:  
• If, during the course of the study, a participant is found not to have met eligibility criteria, the medical monitor, in collaboration with the investigator, will determine 
whether the participant should be withdrawn from study treatment. 
• If a participant is noncompliant with study procedures or study drug administration in 
the investigator 's opi[INVESTIGATOR_1649], the sponsor should be consulted for instruction on handling 
the participant.  
7.1.2. Discontinuation Procedures  
In the event that the decision is made to permanently discontinue the study treatment , the EOT  
visit should be conducted.  Reasonable efforts should be made to have the participant return for a 
follow-up visit.  These visits are described in Table [ADDRESS_1135055] dose 
of study drug(s)/treatment and the reason for discontinuation of study treatment will be recorded in the eCRF.  
If a participant is discontinued from study treatment:  
• The study monitor or sponsor must be notified. 
• The reason(s) for withdrawal must be documented in the participant' s medical record 
and the primary reason for withdrawal must be included in the eCRF.  
• The EOT visit should be performed. 
• The date of the EOT visit should be recorded in the e CRF . 
CONFIDENTIAL  
Incyte Corporation   Page 36 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
• Participants must be followed for safety until the time of the follow -up visit or until 
study drug–related toxicities resolve, return to baseline, or are deemed irreversible, 
whichever is longest.  
If the participant discontinues study treatment and actively withdr aws consent for collection of 
follow-up data (safety follow-up) then no additional data collection should occur; however, participants will have the option of withdrawing consent for study treatment but continuing in the follow-up period of the study for s afety  assessments.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records. 
See Table [ADDRESS_1135056] to follow -up if he/ she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298] . 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact [CONTACT_520717]/or should continue in the study. 
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to r egain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant 's last known mailing address 
or local equivalent methods).  These contact [CONTACT_21457] 's medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study. 
CONFIDENTIAL  
Incyte Corporation   Page 37 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
8. STUDY ASSESSMENTS AND PROCEDURES  
8.1. Administrative and General Procedures  
8.1.1. Informed Consent Process  
• The investigator or his/her represent ative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions 
regarding the study. 
− Informed consent must be obtained before any study- related procedures are 
conducted, unless otherwise s pecified by [CONTACT_89191].  
− Informed consent must be obtained using the IRB/IEC-approved version in a 
language that is native and understandable to the participant.  A template will be provided by [CONTACT_3552].  The sponsor or its designee mus t review 
and acknowledge the site -specific changes to the ICF template.  The ICF must 
include a statement that the sponsor or its designee and regulatory authorities have direct access to participant records.  
− The ICF must contain all required elements and describe the nature, scope, and possible consequences of the study in a form understandable to the study 
participant.  
• Participants must be informed that their participation is voluntary.  Participants or 
their legally authorized representative will be requ ired to sign a statement of informed 
consent that meets the applicable requirements and regulations for the IRB/IEC or 
study center.  
• The participant must be informed that his/her personal study- related data will be used 
by [CONTACT_89192].  The level of disclosure must also be explained to the participant. 
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_6668].  
• The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must 
also sign the ICF. 
• Participants must provide consent to the most current version of the ICF(s) during 
their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant's legally authorized representative. 
Participants who are rescreened are required to sign a new ICF.  
CONFIDENTIAL  
Incyte Corporation   Page 38 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
8.1.2. Screening Procedures  
Screening is the interval between signing the ICF and the day the participant is enrolled  in the 
study (Day  1).  Screening may not exceed 28 days .  Assessments that are required to demonstrate 
eligibility may be  performed over the course of 1  or more days during the screening process. 
Procedures conducted as part of the participant' s routine clinical manag ement (eg, blood count, 
imaging study) and obtained before signing of informed consent may be used for screening or 
baseline purposes provided the procedure meets the Protocol- defined criteria and has been 
performed in the timeframe of the study (ie, within 28 days of Day 1) .  For participants who are 
enroll ed in the study, information associated with eligibility requirements must be entered into 
the appropriate eCRF pages.  
Results from the screening visit evaluations will be reviewed to confirm eligibility  before 
enrollment or the administration of study drug.  Tests with results that fail eligibility requirements may be repeated once during screening if the investigator believes the results to be 
in error.  For screening assessments that are repeated, the most recent available result before 
treatment assignment will be used to determine eligibility .  Treatment should start as soon as 
possible, but within [ADDRESS_1135057] the IRT to obtain the participant ID number during screening.  Upon determining that the participant is eligible for 
study entry, the IRT will be contact[CONTACT_819479].  
Additionally, the IRT will be contact[CONTACT_352971].  Additional details are provided in the IRT manual. 
8.1.4. Distribution of Reminder Cards and/or Diaries  
Participants  will be provided with a reminder card on Day [ADDRESS_1135058] will indicate the date/time of the next visit and will also remind the participant that 
they should not take their morning dose of study drug on the day of each study  visit as they will 
take it after blood draws for safety evaluation have been completed .  The reminder cards for each 
visit will have an area on which the date and time of the last dose taken (from the previous evening) and the time of their last meal befo re the visit should be recorded. 
Participants  will also be provided with a diary on Day [ADDRESS_1135059] dose of study drug  
 will be recorded in the diary and 
eCRF.  Daily study drug administration (see Section  6.1) will also be recorded in the diary.  
CONFIDENTIAL  

Incyte Corporation   Page 40 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
8.2.4. Patient -Reported Outcomes  
Patient -reported outcome instruments will be given to participant s for completion at study visits 
indicated in Table 3.  Site staff will enter completed questionnaires into the eCRF database.  
[IP_ADDRESS]. Dryness Questionnaire 
The d ryness questionnaire will ask participants to r ate the dryness of eyes, mouth, or vagina 
(female participants only) with 24-hour recall  using an 11- point numerical rating system ranging 
from 0 (n o dryness) to 10 ( worst imaginable ; see Appendix B ). 
[IP_ADDRESS]. EULAR Sj ögren's Syndrome Patient Reported Index  
The ESSPRI consists of 3 items, each with a 0 (no symptom) to 10 (maximum imaginable 
symptom) scale.  The 3 items are dryness, fatigue, and pain.  Th e recall period is 2 weeks.  
[IP_ADDRESS]. Patient Global Impression of Change Questi onnaire 
The PGIC asks a single question regarding how the patient is feeling since beginning new 
therapy.  The questionnaire uses a 7 point scale ranging from " very much worse" to " very much 
improved," with the midpoint as no change. 
[IP_ADDRESS]. Female Sexual Function Index  
The FSFI is a brief, self -report measure of female sexual function (female participants only).  
The questionnaire contains 19 items covering 6 domains of sexual function.  The recall period is 
4 weeks.  
[IP_ADDRESS]. PROMIS Fatigue Short Form 
The PROMIS fatigue sh ort form includes 7 items with a rating sale of 1 to 5.  The recall period is 
7 days.  
[IP_ADDRESS]. European Quality Of Life [ADDRESS_1135060] dose of study  drug .  Adverse events that begin or worsen after informed 
consent should be recorded on the Adverse Events F orm in the eCRF  regardless of the 
assumption of a causal relationship with the study drug.  Conditions that were already present at 
the time of informed consent should be recorded on the Medical History F orm in the eCRF .  
Adverse events (including laboratory abnormalities that constitute AEs) should be described using a diagnosis whenever possible rather than by [CONTACT_147108]. 
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally authorized repre sentative) .  The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following-up on AEs that are serious, 
considered related to the s tudy treatment/procedures, or that caused the participant to discontinue 
the study drug.  Care will be taken not to introduce bias when detecting AEs and/or SAEs.  
Open -ended and nonleading verbal questioning of the participant, such as "How are you 
feelin g?" is the preferred method to inquire about AE occurrences .  Adverse events may also be 
detected when they are volunteered by [CONTACT_89198], or through physical examinations, laboratory tests, or other asse ssments.  The definition, 
reporting, and recording requirements for AEs are described in Section  9. 
All SAEs will be recorded and reported to the sponsor or designee within 24 hours.  The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available.  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs  will be followed u ntil resolution, sta bilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3).  
8.3.2. Physical Examinations 
Physical examinations will be conducted at the timepoints listed in Table 3. 
A comprehensive physical examination will include height and body weight and assessment of 
the following organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; 
cardiovascular system; abd omen (liver, spleen); extremities; and lymph nodes.  A brief 
neurological examination will also be performed. 
A targeted physical examination should be conducted as indicated by [CONTACT_312361], AEs, or other findings.  Abnormalities t hat are considered clinically significant in the 
judgment of the investigator are to be reported as AEs. 
Physical examinations must be performed by a medically qualified individual such as a licensed 
physician, physician's assistant, or an advanced registered nurse practitioner, as local law permits . 
8.3.3. Vital Signs  
Vital sign measurements (to be taken before blood collection for laboratory tests) include blood pressure, pulse, respi[INVESTIGATOR_697] , and oral body temperature.  Blood pressure and pulse will be 
CONFIDENTIAL  
Incyte Corporation   Page [ADDRESS_1135061] dose of study treatment constitute an AE if they are considered 
clinically meaningful, induce clinical signs or sympto ms, or require concomitant therapy . 
8.3.4. Electrocardiograms  
Single  12-lead ECG s will be obtained as outlined in the SoA ( see Table 3 ) using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals .  All [ADDRESS_1135062].  
The 12- lead ECGs will be interpreted by [CONTACT_819480].  Additional 12- lead ECGs may be performed as clinically 
indicated to manage participant  safety .  The decision to include or exclude a participant or 
withdraw a participant from the study treatment based on an ECG flagged as "Abnormal, 
Clinically Significant " is the responsibility of the investigator, in consultation with the sponsor' s 
medical monitor, as appropriate.  Clinically notable abnormalities that are considered clinically 
significant in the judgment of the investigator are to be reported as AEs. 
Table 9: Electrocardiogram Schedule 
Study Visit  Timing of Electrocardiogram Relative to Administration of Study Drug 
Not Applicable  Predose (Tro ugh) ECG  Postdose ECG  
Screeninga Single → Tripleb   
Day 1c  Triple  Single → Tripleb 
Week 2c  Single → Tripleb Single → Tripleb 
Week 12d   Single → Tripleb 
a Prolonged QTcF values (> 470 milliseconds for males or > 480 milliseconds for females) at screening are to be confirmed by 
[CONTACT_746] 2 additional ECGs and avera ging the results to determine whether the averaged value meets the exclusion criterion.  
b Singl e → Triple:  Single ECG will be performed first.  If prolonged QTcF interval s (defined as > 470 milliseconds for males or 
> 480 milliseconds for females) are observed, an additional 2 ECGs will be measured within the next 5 minutes.  
c Day 1 and Week 2 postdose ECGs will be performed after participants complete all of the study assessments  
 
d Week12 postdose ECGs will be performed after participants complete all of the study assessments.  
All ECG measurements  should be performed before  blood draws for laboratory  
assessments, a nd all predose (trough) ECG measurements should be taken before the participant  
takes study drug for that day. 
8.3.5. Laboratory Assessments 
See Table [ADDRESS_1135063] of clinical laboratory tests to be performed and the Schedule of 
Laboratory Assessments  (Table 4) for the timing and frequency.  A central laboratory will 
perform all clinical laboratory assessments for safety (ie, blood chemis tries, hematology 
assessments, thyroid  function, and urinalysis) and will store the samples for  PD.  
Additional testing may be required by [CONTACT_89202].  All Protocol-
required laboratory assessments must be conducted in accordance with the laboratory manual 
and t he Schedule of Laboratory Assessments  (Table 4).  Information regarding collection, 
processing, and shippi[INVESTIGATOR_819472]. 
CONFIDENTIAL  

Incyte Corporation   Page [ADDRESS_1135064] was positive, the investigator will assess 
the potential benefit/risk to the participant and determine whether it is in the participant 's best 
interest to resume study drug and continue participation in the study. 
If a pregnancy is confirmed by a serum pregnancy test, see Section  9.6 for rep orting 
requirements.  
[IP_ADDRESS]. Serology and Virology 
Hepatitis  and HIV assessments will be performed at the screening visit to rule out hepatitis or 
HIV infection; required analytes are shown in Table 10.  Serology and virology tests  should be 
performed early in the screening process due to the length of time needed to obtain the results.  
Additional tests may be performed if clinically indicated.  
[IP_ADDRESS]. Tuberculosis  Testing  
Tuberculosis B assessments will be performed at the screeni ng visit.  Test must be performed 
using the QuantiFERON-TB Gold test or T- SPOT.TB test.  If there are [ADDRESS_1135065] with a result of < [ADDRESS_1135066] be 
conducted within 3 months of screeni ng. 
CONFIDENTIAL  

Incyte Corporation   Page 45 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
8.5. Pharmacodynamic and Translational Assessments 
Peripheral blood samples ( eg, serum, PBMC, RNA), tear samples, and saliva samples will be 
collected  from participants at timepoints outlined in Table 4.  All samples for PD and 
translational assessments will be collected before  INCB050465 administration . 
 All analyses will be conducted by 
[CONTACT_819481] (Wilmington, DE) or Incyte's designee.  Information regarding 
handling/shippi[INVESTIGATOR_819473]. 
CONFIDENTIAL  

Incyte Corporation   Page 46 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
8.6. End of Treatment 
If a decision is made that the participant permanently discontinues stud y drug ( early termination) 
or has completed the Protocol-specified duration of treatment, then an EOT visit should be 
conducted.  If the EOT visit coincides with a regular study visit, the EOT evaluations will 
supersede those of that scheduled visit, and the data should be entered in the EOT visit in the 
eCRF.  The participant should be encouraged to return for the safety follow-up visits. 
8.7. Safety Follow -Up 
The safety follow -up period is the interval between the EOT visit and the scheduled follow-up 
visit, w hich should occur 30 to 37 days  after the EOT visit (or after the last dose of study 
drug/treatment if the EOT visit was not performed . 
Adverse events and SAEs must be reported up until at least [ADDRESS_1135067] the participant 
return for the follow -up visit and report any AEs that may occur during this period. 
9. ADVERSE EVENTS:  DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING  
9.1. Definition of Adverse Event  
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug- related.  
• An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.  
Events Meeting  the A dverse Event Definition  
• Any safety assessments (eg ECG, vital signs measurements), including those that worsen from baseline, 
considered clinically significant in the medical and scientific judgment of the investigator (ie, not related to progression of underlying dise ase). 
• Abnormal laboratory test results constitute an AE if they are considered clinically meaningful, induce 
clinical signs or symptoms, require concomitant therapy, or require changes in study drug.   Whenever 
possible, a diagnosis (eg, anemia, thrombocytopenia) should be recorded in the eCRF rather than the abnormal lab result (eg, low hemoglobin, platelet count decreased).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the con dition. 
• New conditions detected or diagnosed after study treatment administration even though they may have been present before the start of the study.  
CONFIDENTIAL  

Incyte Corporation   Page 47 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication .  Overdose per se will not be reported as an AE/SAE unless it is an intentional 
overdose ta ken with possible suicidal/self -harming intent.  Such overdoses shoul d be reported 
regardless of sequelae.  
Events NOT  Meeting the A dverse Event Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by [CONTACT_819482]'s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant 's condition or considered to be 
treatment -related by [CONTACT_093]. 
• Efficacy endpoints as outlined in Section  3 will not be reported as AE/SAEs, specifically, any event 
that is related to disease progression of the cancer  under study.  Unblinded aggregated efficacy endpoint 
events and safety data will be monitored to ensure the safety of the participant s in the study.  Any 
suspected endpoint that upon review is not progression of the cancer under study will be forwarded to 
Incyte Pharmacovigilance as a SAE within 24 hours of determination that the event is not progression 
of the cancer under study. 
• Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to the procedure is the AE if it occurre d after signing informed consent .  If present before entering the study, 
the condition should be captured as medical history.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipated day-to-day fluctuations of pre- existing disease(s) or condition(s) present or detected at the 
start of the study that do not worsen. 
9.2. Definition of S erious Adverse Event 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease). 
A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose:  
a.  Results in death  
b.  Is life -threatening  
The term 'life-threatening ' in the definition of 'serious' refers to an adverse drug experience that places the 
participant, in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse experience as 
it occurred.  This does not include an adverse drug experience that, had it occurred in a more severe form, 
might have caused death . 
c.  Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate in the physician' s office or outpatient setting .  Complications that occur during 
hospi[INVESTIGATOR_227926] A Es.  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether " hospi[INVESTIGATOR_059] " occurred or was necessary, the AE 
should be considered serious. 
CONFIDENTIAL  
Incyte Corporation   Page 48 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
Hospi[INVESTIGATOR_492743] a pre -existing condition that did not worsen from baseline is not 
considered an AE.  
d.  Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person 's ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance , such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained 
ankle) , that may interfere with or prevent everyd ay life functions but do not constitute a substantial 
disruption. 
e.  Is a congenital anomaly/birth defect 
f. Other situations  (Important Medical Event)  
An event that may not result in death, be immediately life -threatening, or require hospi[INVESTIGATOR_059], but may 
be considered serious when, based on appropriate medical judgment, the event may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes listed in the 
above definition.   Examples of such events include invasive or malignant cancers (excluding the 
disease[s] under study in oncology protocols) , intensive treatment in an emergency department or at home 
for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059], or develo pment of drug dependency or drug abuse. 
9.3. Recording and Follow -Up of Adverse Events and/or S erious Adverse 
Event s 
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the Adverse 
Event  Form in the eCRF .  Conditions that were present at the time informed consent was given should 
be recorded on the Medical History Form in the eCRF. 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation  (eg, 
hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
• The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914] 's medical records in lieu 
of completing the AE eCRF page.  
• There may be instances when copi[INVESTIGATOR_63475] .  In this case, all 
participant identifiers, with the exception of the participant number, will be redacted on the copi[INVESTIGATOR_205886].  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information .  Whenever possible, the diagnosis (not the individual signs /symptoms) will 
be documented as the AE/SAE.  When a clear diagnosis cannot be identified, each sign or symptom should be reported as a separate AE /SAE . 
To the extent possible, each AE /SAE  should be evaluated to determine: 
• The severity grade (CTCAE Grade 1  to 5).  See below for further instructions on the assessment of 
intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study drug:  suspected 
(yes) or not suspected (no).  Se e below for further instructions on the asse ssment of causality.  
• The start and end dates, unless unresolved at final follow -up. 
• The action taken with regard to study drug as a result of the AE/SAE (s). 
CONFIDENTIAL  
Incyte Corporation   Page 49 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
• The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown). 
• The seriousness, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event.  Note:  If an AE is treated with a concomitant medicatio n or 
nondrug therapy, this action should be recorded on Adverse Event Form and the treatment should be 
specified on the appropriate eCRF (eg, Prior/Concomitant Medications , Procedures and Non- Drug 
Therapy). 
Assessment of Intensity  
The severity of AEs wil l be assessed using CTCAE v4.03 Grades 1 through 5.  If an event is not 
classified by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the grade of severity:  
The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories:  
• Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment  
not indicated. 
• Grade 2:   Moderate; minimal, local, or noninvasive trea tment  indicated; limiting age appropriate 
activities of daily living.  
• Grade 3:   Severe or medical significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care activities of da ily living.  
• Grade 4:   Life -threatening consequences; urgent treatment  indicated. 
• Grade 5:   Fatal.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment and each occurrence of 
each AE/SAE .   
• A "reasonable possibility " of a relationship conveys that there are facts, evidence, and/or arguments to 
suggest a causal relationship, rather than that a relationship cannot be ruled out. 
• The investigator will use clinical judgment to determine the relationship.  
• The i nvestigator will also consult the RSI in the IB and/or Product Information, for marketed products, 
in his/her assessment.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as 
the temporal relationship of the event to study treatment administration , will be considered and 
investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• With regard to assessi ng causality of SAEs: 
− There may be situations in which an SAE has occurred and the investigator has minimal information 
to include in the initial report.  However,  the causality assessment is one of the criteria used when 
determining regulatory reporting r equirements.  Therefore,  it is very important that the 
investigator always make an assessment of causality for every event before the initial 
transmission of the SAE.  
− The investigator may change his/her opi[INVESTIGATOR_9242] -up information and send a 
follow-up SAE report with the updated causality assessment.  
CONFIDENTIAL  
Incyte Corporation   Page 50 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
Follow -Up of A dverse Events and S erious Adverse Events 
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medical ly indicated or as requested by [CONTACT_22854]/or 
causality of the AE or SAE as fully as possible.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health c are professionals.  
• If a participant dies during participation in the study or during a recognized follow-up period, the investigator will provide the sponsor with a copy of any postmortem findings, including histopathology. 
• New or updated information will be recorded in the originally completed e CRF.  
• Any updated SAE data will be submit ted to the sponsor (or designee) within 24 hours of receipt of the 
information. 
• Once an AE is detected, it should be followed until it has resolved or until it is judged to be permanent; assessment should be made at each visit (or more frequently if necessary) of any changes in severity, 
the suspected relationship to the study drug, the interventions required to treat the event, and the 
outcome. 
• When the severity of an AE changes over time for a reporting period (eg, between visits), each change in severity will be reported as a separate AE until the event resolves. 
9.4. Reporting of S erious Adverse Events 
All SAEs , regardless of suspected causality (eg, relationship to study drug, or study 
procedure[s]) , occurring after the participant has signed the ICF through the last study vis it or 
30 + [ADDRESS_1135068] be reported to the 
sponsor (or designee) within 24 hours  of learning of i ts occurrence, unless otherwise specified 
by [CONTACT_89191].  The investigator will submit any updated SAE data to the sponsor (or designee) 
within 24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE information after c onclusion of the 
study participation .  However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study treatment or study participation, the investigator must notify the 
sponsor (or designee) within 24 hours of becoming aware of the event. 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs  will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3).  
Prompt notification by [CONTACT_11012] a SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study 
treatment under clinical investigation are met. 
If the SAE is not documented in the IB for the study drug (new occurrence) and is thought to be 
related to the sponsor's study drug, the sponsor or its designee may urgently require further 
information from the investigator for reporting to health authorities .  The sponsor or its designee 
may nee d to issue an Investigator Notification to inform all investigators involved in any study 
with the same drug that this SAE has been reported.  Suspected Unexpected Serious Adverse Reactions will be collected and reported to the competent  authorities and re levant ethics 
committees in accordance with Directive 2001/20/EC, or as per national regulatory requirements 
in participating countries.  
CONFIDENTIAL  
Incyte Corporation   Page 51 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies abou t the safety of a study treatment under clinical investigation .  The 
sponsor will comply with country- specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC , and investigators. 
Investigator safety reports must be prepared for suspected unexpected adverse reactions  
according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg summary or listing of SAEs) from the sponsor will review and then file it 
along with the Investigator's Brochure and will notify the IRB/IEC, if appropriate according to 
local requirements.  
Serious Adverse Event Reporting  
• Information about all SAEs is collected and recorded on the Adverse Event Form in the eCRF . 
• The investigator must also complete the Incyte Serious Adverse Event Report Form, in English.  Refer 
to the Incyte Reference Guide for Completing the Serious Adverse Event Repo rt Form.  
• Facsimile or email transmission of the Serious Adverse Event Report Form is the preferred method to 
transmit this information to Pharmacovigilance/designee (eg, C3i/Telerx) .  The contact [CONTACT_819483]'s study- specific representatives is listed in the Study Manual provided to each site.  The 
original copy of the Serious Adverse Event  Report Form and the confirmation sheet must be kept at the 
study site.  
•  
• Follow-up information is recorded on an amended or new Serious Adverse Event  Report Form, with an 
indication that it is follow -up to the previously reported SAE and the date of the original report.  The 
follow-up report should include information that was not provided on the previous Serious Adverse 
Event  Report Form, such as the outcome of the event (eg, resolved or ongoing), treatment provided, 
action taken with study drug because of the SAE (eg, dose reduced, interrupted, or discontinued), or participant disposition (eg, continued or withdrew from study participation) .  Each recurrence , 
complication, or progression of the original event should be reported as follow- up to that event, 
regardless of when it occurs.  
• In rare circumstances, and in the absence of facsimile or computer equipment, notification by [CONTACT_13186] a copy of the Incyte Serious Adverse Event Report Form sent by [CONTACT_20022].  Initial notification via telephone does not replace the need for the investigator to complete and sign the Serious Adverse Event  Report Form within the designated reporting time frames.  
• Contacts for SAE reporting can be found in the Study Manual.  
9.5. Adverse Events of Special Interest  
Adverse events of special interest are defined as occurrences of PJP or other serious infections 
due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens; colitis ; 
and exfoliative dermatitis . 
9.6. Emergency Unblinding of Treatment Assignment  
Not applicable.  
CONFIDENTIAL  
Incyte Corporation   Page [ADDRESS_1135069] interfered with the effectiveness of a contraceptive medication or method .  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study 
drug, the following procedures should be followed in order to ensure safety:  
• The study drug m ust be discontinued immediately. 
• The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy. 
Data on fetal outcome are collected for  regulatory reporting and drug safety evaluation.  
Follow-up should be conducted for each pregnancy to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications, by [CONTACT_89210]-baby [CONTACT_765].  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by [CONTACT_89211].  Pregnancy follow-up information should be 
recorded on the same form and should include an assessment of the possible causal relationship 
to the sponsor's study drug to any pregnancy outcome, as well as follow- up to the first well- baby 
[CONTACT_819484], whichever is later .  Refer to the Incyte 
Reference Guide for Completing the Clinical Trial Pregnancy Form.  
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event  Report Form and submitted to the sponsor or designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and 
must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant's partner, the event should be reported to the sponsor on the Clinical Trial Pregnancy Form. 
9.8. Warnings and Precautions  
Special warnings or precaution s for the study drug , derived from safety information collected by 
[CONTACT_3552], are presented in the IB.  Additional safety information collected 
between IB updates will be communicated in the form of Investigator Not ifications .  Any 
important new safety information should be discussed with the participant during the study, as 
necessary .  If new significant risks are identified, they will be added to the ICF. 
9.9. Product Complaints  
The sponsor collects product complaints on study drugs and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and facilitate 
process and product improvements. 
All product complaints associated with material packaged, labeled, and released by [CONTACT_319862].  All product complaints associated with other 
study material will be reported directly to the respective manufacturer.  
CONFIDENTIAL  
Incyte Corporation   Page [ADDRESS_1135070] error of the mean, 
minimum, maximum, and the 95% confidence interval where appropriate.  Summary statistics will be provided for baseline, the actual mea surements at each visit, and the change and percent 
change from baseline at each visit, if applicable.  All analyses will be implemented using SAS 
version 9.1 or higher. 
10.4.2. Safety Analyses 
Safety analyses will be conducted for the FAS population.  Adverse events will be coded by [CONTACT_252740], and TEAE ( ie, AEs reported for the first time or worsening of a 
pre-existing event after first dose of study drug) will be tabulated by [CONTACT_561532], related events, and ev ents of Grade 3 or higher.  Quantitative safety 
variables and their changes from baseline (laboratory, vital signs, etc) will be summarized with 
descriptive statistics.  Clinically notable abnormal values will be flagged and tabulated based on predefined criteria.  
The clinical laboratory data will be analyzed using summary statistics; no formal treatment group comparisons are planned.  In addition, distributions of key laboratory parameters may be plotted over time; these values will also be classified into  CTCAE toxicity grades and tabulated.  
Descriptive statistics and mean change from baseline will be determined for vital signs at each assessment time.  Vital sign results will be reviewed for clinically notable abnormalities.  
CONFIDENTIAL  

Incyte Corporation   Page 55 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
The se
condary endpoint of change and percent change from baseline in salivary CXCL13 levels 
at Week 4 and 12 will be determined from saliva samples for each participant.   
All analyses will be conducted by [CONTACT_109912] (Wilmington, DE) or Incyte's designee, 
and information regarding handling/shippi[INVESTIGATOR_819474].  
10.5. Interim Analysis  
No formal interim analysis is planned in this study.  
11. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol, Protocol amendments, ICF, IB, and other relevant documents (eg, 
advertisements) must be submitted to an IRB/IEC by [CONTACT_22843]/IEC before the study is initiated . 
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_352981] , the 
policies and procedures established by [CONTACT_1201]/IEC, and institutional requirements. 
• Any amendments to the Protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following: 
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC . 
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures. 
− Providing oversight of the conduct of the study at the site and adherence to GCP , 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country- specific regulations . 
• Adhering to the Protocol as described in this document and agreeing that changes to the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC.  Each investigator is responsible for en rolling participants who have met 
the specified eligibility criteria.  
CONFIDENTIAL  

Incyte Corporation   Page 56 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
• Retaining records in accordance with all local, national, and regulatory laws, but for a 
minimum period of at least [ADDRESS_1135071] article for 
investigation to ensure the availability of study documentation should it become 
necessary fo r the sponsor or a regulatory authority to review. 
− The investigator must not destroy any records associated with the study without 
receiving approval from the sponsor.  The investigator must notify the sponsor or its designee in the event of accidental los s or destruction of any study records.  If 
the investigator leaves the institution where the study was conducted, the sponsor 
or its designee must be contact[CONTACT_89224]. 
− All eCRF data entered by [CONTACT_779] (including audi t trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the site in compliance with applicable record retention regulations.  
The sponsor will retain the original eCRF data and audit trail.  
11.2. Data  Management  
Data management will be performed in a validated EDC system.  The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided eCRF completion guidelines for instructions on data entry in the eCRF.  
The study monitor will reference the Monitoring Plan in order to ensure that each issue identified 
is appropriately documented, reported, and resolved in a timely manner in accordance with the plan's requirements.  
The sponsor (or designee) will be responsible for: 
• The data management of this study including quality checking of the data. 
• Ensuring that study monitors perform ongoing source data verification to confirm that data entered into the eCRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GC P, and all applicable 
regulatory requirements. 
The investigator will be responsible for: 
• Ensuring participant data relating to the study is recorded in the eCRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data, diary data) or as otherwise specified in the Protocol.  The investigator is responsible for verifying 
that data entries are accurate and correct by [CONTACT_46388].  
CONFIDENTIAL  
Incyte Corporation   Page 57 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
• Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF.  
− Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected.  Source documents are filed at the 
investigator 's site.  
− Data entered in the eCRF that are transcribed fr om source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may need to request previous medical records or transfer records, 
depending on the study.  Also, current medical records must be avai lable.  
• Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_89225]. 
− Monitoring:  Qualified representatives of the sponsor or its desig nee, study 
monitors, will monitor the study according to a predetermined plan.  The 
investigator must allow the study monitors to review any study materials and participant records at each monitoring visit.  
− Auditing:  Qualified representatives of the spons or or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol, applicable local clinical study regulations, and overall study conduct.  The investigator must allow the auditors to review original source records and study 
documentation for all participants. 
− Regulatory inspection:  Regulatory authorities may conduct an inspection of the study and the site at any time during the development of an investigational 
product.  The investigator and staff are expected to  cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other 
study-related documents.  The investigator must immediately notify the sponsor when contact[CONTACT_169109]. 
11.3. Data Privacy and Confidentiality of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data privacy laws and regulations.  The investigator and the sponsor or its designee are responsible for ensuring that sensitive information is handl ed in accordance with local requirements (eg, HIPAA) .  
Appropriate consent and authorizations for use and disclosure and/or transfer (if applicable) of protected information must be obtained. 
Participant names will not be supplied to the sponsor or its des ignee .  Only the participant 
number will be recorded in the eCRF, where permitted; if the participant' s name [CONTACT_169117] (eg laboratory report), it must be obliterated on the copy of the document to be 
supplied to the sponsor or its designee.  Study findings stored on a computer will be stored in 
accordance with local data protection laws . 
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_1732] [ADDRESS_1135072]  to Food 
and Drug Administration  Regulation Title 21 CFR Part 54 – Financial Disclosure by [CONTACT_1615] (ie, "covered studies") are required to submit a completed Clinical Investigator 
Financial Disclosure form that sufficiently details any financial interests and arrangements that apply.  For the purpose of this regulation, " clinical investigator " is defined as any investigator or 
subinvestigator who is directly involved in the treatment or evaluation of research participants, including the spouse and each dependent child of the clinical investigator or subinvestigator.  These requirements ap ply to both US and foreign clinical investigators conducting covered 
clinical studies.  
Any new clinical investigators added to the covered clinical study during its conduct must also submit a completed Investigator Financial Disclosure Form.  During a cove red clinical study, 
any changes to the financial information previously reported by a clinical investigator must be reported to the sponsor or its designee.  At the conclusion of the covered clinical study, the clinical investigators will be reminded of their obligations .  In the event that the clinical 
investigator is not reminded, they nevertheless will remain obligated to report to the sponsor or its designee any changes to the financial information previously reported, as well as any changes in their financial information for a period of 1 year after completion of the covered clinical study. 
11.5. Publication Policy  
By [CONTACT_89228], the investigator and his/ her institution agree that the results of the 
study may be used by [CONTACT_456], Incyte Cor poration, for the purposes of national and 
international registration, publication, and information for medical and pharmaceutical professionals.  Study results will be published in accordance with applicable local and national 
regulations.  If necessary, the authorities will be notified of the investigator 's name, address, 
qualifications, and extent of involvement.  The terms regarding the publication of study results 
are contained in the agreement signed with the sponsor or its designee.  A signed agreeme nt will 
be retained by [CONTACT_3552]. 
The results of this study may be published or presented at scientific meetings .  If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.  
This allows the sponsor to protect proprietary information and to provide comments. 
The sponsor will comply with the requirements for publication of study results.  In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data.  In this case, a 
coordinating investigator [INVESTIGATOR_12992]. 
Authorship will be determined in line with International Committee of Medical Jour nal Editors 
authorship requirements. 
CONFIDENTIAL  
Incyte Corporation   Page [ADDRESS_1135073] been collected and a study -site closure visit has been performed. 
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_11004]: 
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines. 
• Inadequate recruitment of participants by [CONTACT_093] . 
• Discontinuation of further study treatment  development. 
CONFIDENTIAL  
Incyte Corporation   Page 60 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
12. REFERENCES  
Baden LR, Bensinger W, Angarone M, e t al. Prevention and treatment of cancer -related 
infections. J Natl Compr Canc Netw 2012;10:1412-1445. 
Bilanc io A, Okkenhaug K, Camps M, et al. Key role of the p110δ isoform of PI3K in B- cell 
antigen and IL -4 receptor signaling: comparative analysis of genetic and pharmacologic 
interference with p110δ function in B cells. Blood 2006;107:642-650. Bombardieri M, Lewis M, Pi[INVESTIGATOR_214948] C.  Ectopic lymphoid neogenesis in rheumatic autoimmune 
diseases. Nat Rev Rheumatol 2017;13:141-154. 
Brito -Zerón P, Ramos -Casals M;  EULAR -SS task force group. Advances in the understanding 
and treatment of systemic complications in Sjögren's syndrome. Curr Opin Rheumatol 
2014;26:520-527. 
Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657. 
Carsons SE, Bhimji SS. Sjogren Syndrome. StatPearls [Internet]. Treasure Island (FL): 
StatPearls Publishing; [ADDRESS_1135074] 1. 
Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy 
testing in clinical trials. 2014. http://www.hma.eu/c tfg.html. Accessed MAR 20, 2018.  
Fazaa A, Bourcier T, Chatelus E, et al. Classification criteria and treatment modalities in primary 
Sjögren's syndrome. Expert Rev Clin Immunol 2014;10:543-551. 
Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye 
associated with Sjögren disease. Ocul Surf 2015;13:118-132. 
Fung -Leung WP. Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function. 
Cell Signal 2011;23:603-608. Gazeau P , Cornec D, Jousse-Joulin S, Guellec D, Saraux A, Devauchelle- Pensec V. Time -course 
of ultrasound abnormalities of major salivary glands in suspected Sjogren’s syndrome. Joint 
Bone Spi[INVESTIGATOR_050] 2018;85:227-232. 
Henley T, Kovesdi D, Turner M. B-cell responses to B- cell activation factor of the TNF family 
(BAFF) are impaired in the absence of PI3K delta. Eur J Immunol 2008;38:3543-3548. 
INCB0 [ADDRESS_1135075] igator's Brochure. Wilmington, DE: Incyte Corporation. 
Jin L, Yu D, Li X, Yu N, et al. CD4+CXCR5+ follicular helper T cells in salivary gland promote 
B cells maturation in patients with primary Sjogren’s syndrome. Int J Clin Exp Pathol 
2014;7:1988-1996. 
Kang HI, Fei HM, Saito I, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and 
Japanese patients with primary Sjögren's syndrome. J Immunol 1993;150:3615-3623. 
Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers 
2017;3:[ZIP_CODE]. 
CONFIDENTIAL  
Incyte Corporation   Page [ADDRESS_1135076] CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and 
adaptive immune responses are associated with Sjögren’s Syndrome. Nat Genet 2013;34:1284-
1292. 
Maehara T, Moriyama M, Hayashida JN, et al. Selective l ocalization of T helper subsets in labial 
salivary glands from primary Sjögren’s syndrome patients. Clin Exp Immunol 2012;169:89-99. 
Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3- kinase – 
moving towards therapy. Biochim Biophys Acta 2008;1784:159-185. 
Mayne CG, Williams CB.  Induced and natural regulatory T cells in the development of 
inflammatory bowel disease.  Inflamm Bowel Dis 2013;19:1772-1788. 
Patton DT, Garden OA, Pearce WP, et al. Cutting edge: the phosphoinositide 3-kinase p110δ is 
critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2006;177:6598-
6602. 
Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca 
symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis 1999;58:423-427. 
Phillips TJ, Ramchandren R, Wertheim MS, et al. An ongoing open-label phase 1/2 study of 
INCB050465, a selective PI3Kδ inhibitor, in patients with previously treated B- cell 
malignancies. Blood 2016;128:4195. Pi[INVESTIGATOR_24124] S, Cariappa A. The f ollicular versus marginal zone B lymphocyte cell fate decision. Nat 
Rev Immunol 2009;9:767-777. 
Pi[INVESTIGATOR_53396], Matteson EL, Jacobsson LT, et al. Incidence of physician -diagnosed primary 
Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001;76:593-
599. 
Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B- cell 
function with potential for treating autoimmune inflammatory diseases and B -cell malignancies. 
Front Immunol 2012;3:256. Qin B, Wang J, Yang  Z, et al. Epi[INVESTIGATOR_410773]ögren's syndrome: a systematic review 
and meta-analysis. Ann Rheum Dis 2015;74:1983-1989. Ramos -Casals M, Brito -Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topi[INVESTIGATOR_819475]ögren's syndrome. Nat Rev Rheumatol 2012;8:399-
411. Ramos -Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and 
therapeutic concepts. Ann Rheum Dis 2005;64:347-354. 
Ramos -Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren 
syndrome: a systematic review. JAMA 2010;304:452-460. 
Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. Cutting edge: 
differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis 
and homing. J Immunol 2004;173:2236-2240. 
CONFIDENTIAL  
Incyte Corporation   Page 62 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
Risselada AP, Kruize AA, Goldschmeding R, Lafeber FP, Bijlsma JW, van Roon JA. The 
prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's 
syndrome. Ann Rheum Dis 2014;73:1537-1540. 
Rolf J, Bell SE, Kovesdi D et al. Phosphoinositide 3- kinase activity in T cells regulates the 
magnitude of the germinal center reaction. J Immunol 2010;185:4042-4052. 
Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ctopic germinal ce nter 
formation and autoantibody production in the target organ of patients with Sjögren’s syndrome. 
Arthritis Rheum 2003;48:3187-3201. 
Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev 
Rheumatol 2016;12:456-471. 
Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjögren's syndrome disease 
activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859-866. Szabo K, Papp G, Dezso B and Zeher M.  The histopathology of labial salivary glands in prim ary 
Sjögren’s syndrome: focusing on follicular helper T cells in the inflammatory infiltrates.  
Mediators Inflamm 2014;2014:631787. DOI:10.1155/2014/631787. 
Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapi[INVESTIGATOR_014]. 
Semin A rthritis Rheum 2008;37:273-292. 
Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011;70:1363-1368. 
Vigorito E, Bardi G, Glassford J, Lam EW, Clayton E, Turner M. Vav-dependent and 
vav-independent phosphatidylinositol 3- kinase activation in murine B cells determined by [CONTACT_819485]. J Immunol 2004;173:3209-3214. 
Vitali C. Classification criteria for Sjögren's syndrome. Ann Rheum Dis 2003;62:94-95. 
Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a 
revised version of the European criteria proposed by [CONTACT_317921]-European Consensus Group. 
Ann Rheum Dis 2002;61:554-558. 
Vivino FB, Carsons SE, Foulks G, et al. New Treatment Guidelines for Sjögren's Disease. 
Rheum Dis Clin North Am 2016;42:531-551. 
CONFIDENTIAL  
Incyte Corporation   Page 63 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
APPENDIX A. INFORMATION REGARDING EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S 
For male participants in the study:  
Male  participants should use a condom during treatment and through [ADDRESS_1135077] had a vasectomy qualify as having met the requirement 
for a highly effective birth control method. 
For female participants in the study:  
The following methods that can achieve a failure rate of less than 1% per year when used 
consistently and correctly are considered as highly effective birth control methods: 
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulationa 
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulationa 
− oral 
− injectable  
− implantableb 
• Intrauterine deviceb 
• Intrauterine hormone- releasing systemb 
• Bilateral tubal occlusionb 
• Vasectomi zed partnerb c 
• Sexual abstinenced 
Acceptable birth control methods that result in a failure rate of more than 1% per year include:  
• Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary 
mode of action 
• Male or female condom with or without spermicidee 
• Cap, diaphragm or sponge with spermicidee 
• Tubal ligation  
a Hormonal contraception may be susceptible to interaction with the investigational medicinal product, which may 
reduce the efficacy of the contraception method.  
b Contraception methods that in the context of this guidance are considered to have low user dependency.  
c Vasectomized partner is a highly effective method of avoiding pregnancy provided that  partner is the sole sexual 
partner of the woman of childbearing potential study participant and that the vasectomized partner has received 
medical assessment of the surgical success.  
d In the co ntext of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.  The 
reliability of sexual abstinence needs  to be evaluated in relation to the duration of the clinical study and the 
preferred and usual lifestyle of the participant.  
e A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods) 
are also considered acceptable, but not highly effective, birth control methods.  
Source:  Clinical Trials Facilitation Group  2014. 
CONFIDENTIAL  
Incyte Corporation   Page [ADDRESS_1135078]  dryness 
of your mouth?  0-10 scale  
0 = No dryness, 
10 = Worst  Imaginable  
2. During the past [ADDRESS_1135079]  dryness 
of your eyes?  0-10 scale  
0 = No dryness, 
10 = Worst  Imaginable  
FOR FEMALE PARTICIPANTS ONLY 
3. During the past [ADDRESS_1135080] dryness 
of your vagina?  0-10 scale  
0 = No dryness, 
10 = Worst  Imaginable  
CONFIDENTIAL  
Incyte Corporation   Page 65 of 65 
Protocol INCB [ZIP_CODE]- 207 Version 0  12 JUN 2018  
APPENDIX C. PROTOCOL AMENDMENT SUMMARY OF CHANGES  
Not applicable.  
CONFIDENTIAL  